about
Purinergic Signalling: Therapeutic Developments.Purinergic signaling in infection and autoimmune disease.The inflammasome: Friend or foe in Chlamydia infection?The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Purinergic signaling in schistosomal infection
@ast
Purinergic signaling in schistosomal infection
@en
Purinergic signaling in schistosomal infection
@nl
type
label
Purinergic signaling in schistosomal infection
@ast
Purinergic signaling in schistosomal infection
@en
Purinergic signaling in schistosomal infection
@nl
prefLabel
Purinergic signaling in schistosomal infection
@ast
Purinergic signaling in schistosomal infection
@en
Purinergic signaling in schistosomal infection
@nl
P2860
P356
P1433
P1476
Purinergic signaling in schistosomal infection
@en
P2093
Claudia Lucia Martins Silva
P2860
P304
P356
10.1016/J.BJ.2016.06.006
P407
P577
2016-10-01T00:00:00Z